Cargando…

Population Exposure‐Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid‐Induced Constipation

Naloxegol is approved for the treatment of opioid‐induced constipation (OIC) in adults with chronic noncancer pain. Population exposure‐response models were developed using data from a phase II study comprising 185 adults with OIC. The weekly probability of response defined as having ≥3/week spontan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al‐Huniti, Nidal, Xu, Hongmei, Zhou, Diansong, Aksenov, Sergey, Fox, Robert, Bui, Khanh H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658281/ https://www.ncbi.nlm.nih.gov/pubmed/28782266 http://dx.doi.org/10.1002/psp4.12229

Ejemplares similares

Population Exposure‐Response Modeling of Naloxegol in Patients With Noncancer‐Related Pain and Opioid‐Induced Constipation
por: Al‐Huniti, N, et al.
Publicado: (2016)

Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation
por: Floettmann, Eike, et al.
Publicado: (2017)

Clinical utility of naloxegol in the treatment of opioid-induced constipation
por: Bruner, Heather C, et al.
Publicado: (2015)

Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients’ Health State Utility
por: Lawson, Richard, et al.
Publicado: (2016)

Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation
por: Lemaire, Antoine, et al.
Publicado: (2021)

Evaluating the Safety and Efficacy of Naloxegol in Critically Ill Opioid-Induced Constipation Patients
por: Rizwan, M. Zeeshan, et al.
Publicado: (2023)

Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation
por: Anantharamu, Tejus, et al.
Publicado: (2015)

Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem
por: Yoon, Stephanie C, et al.
Publicado: (2017)

Correction to: Effectiveness of naloxegol in patients with cancer pain suffering from opioid‑induced constipation
por: Lemaire, Antoine, et al.
Publicado: (2021)

Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
por: Zhou, D, et al.
Publicado: (2016)

Naloxegol to Prevent Constipation in ICU Adults Receiving Opioids: A Randomized Double-Blind Placebo-Controlled Pilot Trial
por: Duprey, Matthew S., et al.
Publicado: (2022)

Effect of Naloxegol on Opioid-Induced Esophageal Motility Disorder
por: Ulteig, Crista, et al.
Publicado: (2022)

A Prospective, Real-World, Multinational Study of Naloxegol for Patients with Cancer Pain Diagnosed with Opioid-Induced Constipation—The NACASY Study
por: Davies, Andrew, et al.
Publicado: (2022)

Absorption, distribution, metabolism, and excretion of [(14)C]-labeled naloxegol in healthy subjects
por: Bui, Khanh, et al.
Publicado: (2015)

Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction
por: Poulsen, Jakob Lykke, et al.
Publicado: (2014)

Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis
por: Cobo Dols, Manuel, et al.
Publicado: (2021)

A Randomized, Multicenter, Prospective, Crossover, Open-Label Study of Factors Associated With Patient Preferences for Naloxegol or PEG 3350 for Opioid-Induced Constipation
por: Brenner, Darren M., et al.
Publicado: (2019)

Efficacy and Safety of Naloxegol in Patients with Chronic Non-Cancer Pain Who Experience Opioid-Induced Constipation: A Pooled Analysis of Two Global, Randomized Controlled Studies
por: Chey, William D, et al.
Publicado: (2023)

Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non‐Small Cell Lung Cancer
por: Nagase, Mario, et al.
Publicado: (2020)

Naloxegol and Postoperative Urinary Retention: A Randomized Trial
por: Turan, Alparslan, et al.
Publicado: (2022)

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities
por: Al‐Huniti, Nidal, et al.
Publicado: (2020)

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
por: Webster, Lynn R, et al.
Publicado: (2015)

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

Improved Process for the Preparation of Naloxegol Oxalate, an Opiod Receptor Antagonist
por: Velugula, Siva Rama Kasibabu, et al.
Publicado: (2023)

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain [Corrigendum]
Publicado: (2018)

Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach
por: Zhou, Diansong, et al.
Publicado: (2019)

Naloxegol hydrogen oxalate displaying a hydrogen-bonded layer structure
por: Gelbrich, Thomas, et al.
Publicado: (2018)

Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
por: Ostan, Rita, et al.
Publicado: (2021)

Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies
por: Saito, Yoji, et al.
Publicado: (2018)

Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer
por: Katakami, N, et al.
Publicado: (2018)

Effects of Naloxegol on Gastrointestinal Transit and Colonic Fecal Volume in Healthy Participants Receiving Oxycodone
por: Olesen, Anne E, et al.
Publicado: (2019)

Constipation in Elderly Patients with Noncancer Pain: Focus on Opioid-Induced Constipation
por: Chokhavatia, Sita, et al.
Publicado: (2016)

Methylnaltrexone in the treatment of opioid-induced constipation
por: Meerveld, Beverley Greenwood-Van, et al.
Publicado: (2008)

Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis
por: Zhang, Xin, et al.
Publicado: (2017)

Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial Dose
por: Chamberlain, Bruce H, et al.
Publicado: (2023)

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia
por: Pu, Xia, et al.
Publicado: (2021)

Abdominal Pain due to Opioid-Induced Constipation
por: Jacobs, Chelsea, et al.
Publicado: (2019)

Opioid-Induced Constipation in Advanced Cancer Patients
por: ALMouaalamy, Nabil
Publicado: (2021)

Impact of opioid-induced constipation on opioid substitution therapy management: the patient perspective
por: Lugoboni, Fabio, et al.
Publicado: (2021)

Opioid-Induced Constipation: Pathophysiology, Clinical Consequences, and Management
por: Kumar, Lalit, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1iasbi39rj7nvlbnlqhc5minci